Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Front Immunol. 2018 Mar 26;9:584. doi: 10.3389/fimmu.2018.00584. eCollection 2018.
Breast cancer (BC) is the second most common cause of cancer mortality of women worldwide. BC is a systemic disease with a highly heterogeneous course of disease. Therefore, prognostic and diagnostic biomarkers are required to improve the clinical risk management. Cancer-derived or cancer-associated extracellular vesicles (EVs) procured from the bloodstream of BC patients offer a novel platform for the qualitative and quantitative screening and establishment of biomarkers. Here, we focus on common aspects of EVs, on the function of BC-derived EVs and their translational potential considering the EV abundancy, intravesicular as well as outer membrane-anchored composition and current challenges of implementation in clinical practice.
乳腺癌（BC）是全球女性癌症死亡的第二大常见原因。BC 是一种全身性疾病，具有高度异质性的疾病过程。因此，需要预后和诊断生物标志物来改善临床风险管理。从乳腺癌患者的血液中提取的癌症衍生或与癌症相关的细胞外囊泡（EVs）为定性和定量筛选以及建立生物标志物提供了一个新的平台。在这里，我们重点介绍 EV 的常见方面，考虑到 EV 的丰度、囊内和外膜锚定组成以及在临床实践中实施的当前挑战，探讨了 BC 衍生 EV 的功能及其转化潜力。
